Dr. Daniel Peng is currently a Director in Global Regulatory Affairs CMC at Merck where he supports investigational and commercial programs for Merck’s biologic products.
From 2010 to 2016, Daniel served as primary and secondary CMC reviewer for various types of regulatory submissions in the Office of Generic Drugs (OGD) and Office of Pharmaceutical Quality (OPQ) in CDER of US FDA.
Daniel has also worked in leading global pharmaceutical companies (Shire and AstraZeneca) for pharmaceutical product development and commercial manufacturing for seven years. Prior to this, he spent six years as a faculty member at College of Pharmacy, University of Tennessee Health Science Center (Memphis, TN).
Daniel obtained his Ph.D. in Pharmaceutics in 1998 from West China University of Medical Sciences (Chengdu, China).